The discovery that cellular development is not a one-way street has earned this year's Nobel Prize in physiology or medicine. John B. Gurdon, a developmental biologist at the Wellcome Trust/Cancer Research UK Gurdon Institute at the University of Cambridge in the United Kingdom, and Shinya Yamanaka, a stem cell researcher at Kyoto University in Japan and the Gladstone Institute at the University of California, San Francisco, have won the prize for their discovery that mature cells can be reprogrammed to resemble the versatile cells of a very early embryo. These so-called pluripotent cells have the ability to become any of the body's tissues. The pair's work, which bridges two eras of modern biology, "revolutionised our understanding of how cells and organisms develop," the Nobel committee wrote in its award announcement.

The ability to reprogram adult cells has made it possible for researchers to study certain diseases in new ways and raises the possibility of someday growing replacement tissues or even organs in the lab. "I think everyone who works on developmental biology and on the understanding of disease mechanisms will applaud these excellent and clear choices for the Nobel prizes. "Countless labs' work build on the breakthroughs they have pioneered," says John Hardy, a neuroscientist the University College London.

In normal development, cells mature from their pluripotent state into various, specialized cell types a neuron, muscle cell, or skin cell, for example. For many years developmental biologists thought that the cellular maturation process was irreversible. In 1962, however, John Gurdon, working at the University of Oxford, showed that under the right conditions, a mature cell nucleus could become developmentally young again. He replaced the nucleus of a frog egg with a nucleus taken from a cell in a tadpole's intestine. In a few cases, the egg cell was able to "reprogram" the DNA in the tadpole nucleus and the egg cell developed into an adult frog-the first animals cloned from mature cells*. Other researchers built on Gurdon's findings, most famously the team that cloned Dolly the sheep using a similar feat of nuclear transplantation. That breakthrough demonstrated that mammal cells could undergo the same transformation from mature to immature.

More than 4 decades later, Shinya Yamanaka showed that an egg cell wasn't necessary to reprogram a cell's DNA to pluripotency. Working with mouse cells, Yamanaka and his colleagues found that by adding extra copies of four genes to skin cells growing in a laboratory dish, they could prompt the cells to act like embryonic stem (ES) cells, the pluripotent cells taken from early embryos. A few years later, Yamanaka and other teams showed that a similar technique could work on human cells. That has allowed scientists to establish stable, growing populations of cells from patients with diseases such as Amyotrophic Lateral Sclerosis. Researchers can study such cells, known as induced pluripotent stem (iPS) cells for disease insights. In the case of ALS, for example, they can prompt them to become muscle and nerve cells that mimic the problems seen in people with the condition. Yamanaka, who originally trained as an orthopedic surgeon, welcomed the Nobel honor with a note of caution about how quickly it might yield medical benefits. "I feel great joy, but at the same time a great responsibility. The iPS technology is new and we actually have not been able to apply these findings to the development of new therapies or drugs. I feel we have to continue research to make a contribution to society as early as possible."

Yamanaka's work was also welcomed because it offers researchers a potential alternative to human ES cells, which have been ethically and politically controversial given their source. Scientists are still working to understand exactly how cells reprogrammed by the addition of genes differ from the pluripotent cells that are found in embryos, and how those differences might affect the ways the cells can be used.

Gurdon released a statement highlighting how the two scientist's research had moved from basic science into medicine: "I am immensely honoured to be awarded this spectacular recognition, and delighted to be due to receive it with Shinya Yamanaka, whose work has brought the whole field within the realistic expectation of therapeutic benefits. ... It is particularly pleasing to see how purely basic research, originally aimed at testing the genetic identity of different cell types in the body, has turned out to have clear human health prospects."

At the press conference at Kyoto University today, Yamanaka said that he couldn't have carried out his work without the financial support he has received from the country." I really feel that Japan is receiving this prize." In 2009, he and Gurdon shared the Albert Lasker Basic Medical Research Award.

Is this the mRNA reprogramming method? Can it be that someone is FINALLY recognizing this discovery? IF so, then MAYBE NOW there will be an appropriate level of finance directed at this discovery of the “holy grail” of regenerative technology.

I don’t know when the final choice was made, but I was told during a picnic, August 4th, that Yamanaka would be a winner this time ... and he richly deserves the award. My source told me ‘Yamanaka was acutely focused upon developing stem cell sources that would not kill human beings to get them.’

Puhleeze! These guys were awarded a Nobel for that esoteric stuff? Give me a break! barack hussein obama, mmm, mmm, mmm won it for an actual accomplishment, or something. (do I really need the /sarc tag?)

IIRC, Yamanaka used modified adenoviruses to deliver four genes to fibroblasts to get his iPS cells. He later found he could do without the gene called c-myc, which was thought to be oncogenic, IIRC. Check the video at the PBS link.

My source told me Yamanaka was acutely focused upon developing stem cell sources that would not kill human beings to get them.

Check the video at the PBS link. Yamanaka seemed resigned to the fact that iPS cells will have to be compared against human embryonic stem cells(HESC). I've read that iPS cells retain at least some epigenetic imprinting from their somatic cell origin. I read a BBC story yesterday from last July about using HESC in a dozen chronic stroke victims in a phase I trial in Scotland. IIRC, the doc's last name was Muir. The BBC story didn't mention it, but when I checked some more on the web and then at PubMed, immunosuppressant drugs were involved.

My source told me Yamanaka was acutely focused upon developing stem cell sources that would not kill human beings to get them.

Check the video at the PBS link. Yamanaka seemed resigned to the fact that iPS cells will have to be compared against human embryonic stem cells(HESC). I've read that iPS cells retain at least some epigenetic imprinting from their somatic cell origin. I read a BBC story yesterday from last July about using HESC in a dozen chronic stroke victims in a phase I trial in Scotland. IIRC, the doc's last name was Muir. The BBC story didn't mention it, but when I checked some more on the web and then at PubMed, immunosuppressant drugs were involved.

Disclaimer:
Opinions posted on Free Republic are those of the individual
posters and do not necessarily represent the opinion of Free Republic or its
management. All materials posted herein are protected by copyright law and the
exemption for fair use of copyrighted works.